• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有事件发生时间终点的活性对照非劣效性试验中的比值检验。

A ratio test in active control non-inferiority trials with a time-to-event endpoint.

作者信息

Wang Yong-Cheng, Chen Gang, Chi George Y H

机构信息

Biostatistics, Centocor, Inc., Malvern, Pennsylvania 19355, USA.

出版信息

J Biopharm Stat. 2006;16(2):151-64. doi: 10.1080/10543400500508754.

DOI:10.1080/10543400500508754
PMID:16584064
Abstract

There are essentially two kinds of non-inferiority hypotheses in an active control trial: fixed margin and ratio hypotheses. In a fixed margin hypothesis, the margin is a prespecified constant and the hypothesis is defined in terms of a single parameter that represents the effect of the active treatment relative to the control. The statistical inference for a fixed margin hypothesis is straightforward. The outstanding issue for a fixed margin non-inferiority hypothesis is how to select the margin, a task that may not be as simple as it appears. The selection of a fixed non-inferiority margin has been discussed in a few articles (Chi et al., 2003; Hung et al., 2003; Ng, 1993). In a ratio hypothesis, the control effect is also considered as an unknown parameter, and the noninferiority hypothesis is then formulated as a ratio in terms of these two parameters, the treatment effect and the control effect. This type of non-inferiority hypothesis has also been called the fraction retention hypothesis because the ratio hypothesis can be interpreted as a retention of certain fraction of the control effect. Rothmann et al. (2003) formulated a ratio non-inferiority hypothesis in terms of log hazards in the time-to-event setting. To circumvent the complexity of having to deal with a ratio test statistic, the ratio hypothesis was linearized to an equivalent hypothesis under the assumption that the control effect is positive. An associated test statistic for this linearized hypothesis was developed. However, there are three important issues that are not addressed by this method. First, the retention fraction being defined in terms of log hazard is difficult to interpret. Second, in order to linearize the ratio hypothesis, Rothmann's method has to assume that the true control effect is positive. Third, the test statistic is not powerful and thus requires a huge sample size, which renders the method impractical. In this paper, a ratio hypothesis is defined directly in terms of the hazard. A natural ratio test statistic can be defined and is shown to have the desired asymptotic normality. The demand on sample size is much reduced. In most commonly encountered situations, the sample size required is less than half of those needed by either the fixed margin approach or Rothmann's method.

摘要

在活性对照试验中,本质上有两种非劣效性假设:固定界值假设和比率假设。在固定界值假设中,界值是预先设定的常数,该假设是根据一个单一参数来定义的,这个参数表示活性治疗相对于对照的效应。对固定界值假设的统计推断很直接。固定界值非劣效性假设的突出问题是如何选择界值,这项任务可能不像看起来那么简单。一些文章(Chi等人,2003年;Hung等人,2003年;Ng,1993年)已经讨论了固定非劣效界值的选择。在比率假设中,对照效应也被视为一个未知参数,然后非劣效性假设根据这两个参数(治疗效应和对照效应)被表述为一个比率。这种类型的非劣效性假设也被称为效应保留假设,因为比率假设可以解释为对照效应的一定比例的保留。Rothmann等人(2003年)在生存时间设定中根据对数风险制定了一个比率非劣效性假设。为了规避处理比率检验统计量的复杂性,在对照效应为正的假设下,比率假设被线性化为一个等价假设。针对这个线性化假设开发了一个相关的检验统计量。然而,这种方法没有解决三个重要问题。第一,根据对数风险定义的保留比例难以解释。第二,为了使比率假设线性化,Rothmann的方法必须假设真实的对照效应为正。第三,检验统计量的功效不强,因此需要巨大的样本量,这使得该方法不切实际。在本文中,比率假设直接根据风险来定义。可以定义一个自然的比率检验统计量,并且证明它具有所需的渐近正态性。对样本量的要求大大降低。在最常见的情况下,所需样本量不到固定界值方法或Rothmann方法所需样本量的一半。

相似文献

1
A ratio test in active control non-inferiority trials with a time-to-event endpoint.具有事件发生时间终点的活性对照非劣效性试验中的比值检验。
J Biopharm Stat. 2006;16(2):151-64. doi: 10.1080/10543400500508754.
2
A more powerful test based on ratio distribution for retention noninferiority hypothesis.一种基于比率分布的用于保留非劣效性假设的更强大检验。
J Biopharm Stat. 2013 Mar 11;23(2):346-60. doi: 10.1080/10543406.2011.616968.
3
Choice of delta noninferiority margin and dependency of the noninferiority trials.δ非劣效界值的选择及非劣效性试验的依赖性
J Biopharm Stat. 2007;17(2):279-88. doi: 10.1080/10543400601177384.
4
Design and analysis of non-inferiority mortality trials in oncology.肿瘤学中非劣效性死亡率试验的设计与分析
Stat Med. 2003 Jan 30;22(2):239-64. doi: 10.1002/sim.1400.
5
Issues on the selection of non-inferiority margin in clinical trials.临床试验中非劣效界值选择的相关问题。
Chin Med J (Engl). 2009 Feb 20;122(4):466-70.
6
Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?肿瘤学中的活性对照非劣效性试验:任意限制、不可行的样本量和无信息的数据分析。是否有其他方法?
Pharm Stat. 2006 Oct-Dec;5(4):283-93. doi: 10.1002/pst.218.
7
Some fundamental issues with non-inferiority testing in active controlled trials.活性对照试验中非劣效性检验的一些基本问题。
Stat Med. 2003 Jan 30;22(2):213-25. doi: 10.1002/sim.1315.
8
Use of the Fieller-Hinkley distribution of the ratio of random variables in testing for noninferiority.在非劣效性检验中使用随机变量比率的菲勒 - 欣克利分布。
J Biopharm Stat. 2007;17(2):215-28. doi: 10.1080/10543400601177335.
9
Mixed noninferiority margin and statistical tests in active controlled trials.活性对照试验中的混合非劣效性界值与统计检验。
J Biopharm Stat. 2007;17(2):339-57. doi: 10.1080/10543400601183861.
10
On non-inferiority analysis based on delta-method confidence intervals.基于德尔塔法置信区间的非劣效性分析。
J Biopharm Stat. 2003 Aug;13(3):565-83. doi: 10.1081/BIP-120022775.

引用本文的文献

1
The generalized inference on the ratio of mean differences for fraction retention noninferiority hypothesis.分数保留非劣效假设中平均差比的广义推断。
PLoS One. 2020 Jun 9;15(6):e0234432. doi: 10.1371/journal.pone.0234432. eCollection 2020.